Chump
My point is, even if we have good data...We absolutely need to hand the drug over to some entity..including HC, which still falls into a BO category. BP OR HC...100% BO Necessitated. CYDY could never launch this product..even with superior data. So yes Chump, HC would be one of those savior Suitors. Of course, the stronger the data the better probability for a BO. I do get nervous about the data..first, will it hit the Primary End point criteria, second, will we get FDA approval..and then, and the most important aspect of all, will a larger commercializing Bio Pharma buy us out, based on their Due Diligence within the HIV space. In other words, will this be a viable ROI..even with approval.